Lantern Pharma Advances Lung Cancer Trial After Positive FDA Feedback

Lantern Pharma (NASDAQ: LTRN) announced positive FDA feedback following a recent Type C meeting regarding its ongoing Phase 2 Harmonic trial evaluating LP-300 for never-smokers with advanced non-small cell lung cancer (NSCLC). The FDA raised no objections to the company’s proposed protocol amendments, helping establish a clearer regulatory path forward for the program.

Lantern says never-smoker NSCLC is increasingly recognized as a distinct disease with unique clinical and genomic characteristics, affecting an estimated 400,000 to 500,000 patients globally each year. The company believes LP-300 could address a major unmet need within this specialized patient population.

#LanternPharma
#LTRN
#LungCancer
#NSCLC
#Biotech
#Oncology
#ClinicalTrials
#FDA
#CancerResearch
#PrecisionMedicine
#ArtificialIntelligence
#DrugDevelopment
#HealthcareInnovation
#JaneKing
#NewsOut